Buildner announces winners of the 2023 Architect s Sugar Architectural Visualization competition. Now in its second year, the competition called for participants to
How estrogen receptor-positive (ER+) breast cancer responds to hormone therapy may hold keys to understanding how it will respond to radiation therapy, and an experimental drug that increases the effectiveness of hormone therapy also overcomes radiation resistance in breast cancer, a study by UT Southwestern Medical Center researchers shows.
For patients with estrogen receptor (ER)-positive breast cancer, development of the so-called Y537S mutation signals that their disease has taken an aggressive course and may become resistant to endocrine therapy.
DALLAS – Nov. 15, 2022 – For patients with estrogen receptor (ER)-positive breast cancer, development of the so-called Y537S mutation signals that their disease has taken an aggressive course and may become resistant to endocrine therapy.